

March 31, 2026

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G - Block  
Bandra –Kurla Complex, Bandra (E)  
Mumbai – 400 051

Dear Sir/ Madam,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Dr. Shashank Srinivasan as Medical Director – Oncology Business Unit, with effect from April 1, 2026.

Also, further to our communication dated December 1, 2023, we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the promotion of Mr. Venkat Natarajan to Director – Market Access Business Unit from Lead – Market Access, effective April 1, 2026.

These being Senior Management Personnel position in terms of the SEBI Listing Regulations, please find the details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking you,

**For AstraZeneca Pharma India Limited**

**Tanya Sanish**

**Company Secretary & Compliance Officer**

**Annexure - A**

Sl. No.	Particulars	Dr. Shashank Srinivasan	Mr. Venkat Natarajan
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Dr. Shashank Srinivasan as Medical Director – Oncology Business Unit	Mr. Venkat Natarajan as Director – Market Access Business Unit
2	Date of appointment/cessation (as applicable) and term of appointment	Effective April 1, 2026  Term of appointment – Full – time employment	Effective April 1, 2026  Term – Full – time employment
3	Brief Profile	<p>Dr. Shashank Srinivasan is a clinical oncologist and alumnus of Tata Memorial Hospital (TMH), Mumbai. At TMH, he served as a consultant in the GI Cancers Disease Management Group within the Division of Radiation Oncology, contributing to multidisciplinary care and translational practice. Academically, he holds a DNB in Radiation Oncology from Max Super Speciality Hospital, Vaishali. His strong scientific grounding is further reinforced by contributions to oncology research.</p> <p>Dr. Shashank is an Oncology industry leader, having begun his journey with Pfizer, where he served as the medical lead for the lung cancer portfolio. At Pfizer, he led industry-leading initiatives to nurture the ALK+ NSCLC therapy area, resulting in significant patient impact. He subsequently served as the Therapy Area Lead for GI and Lung Cancers at AstraZeneca, blending his clinical experience with strategic nuance to lead transformative projects that improve patient outcomes. He has successfully driven multiple new launches with a proven track record of</p>	<p>Mr. Venkat Natarajan is a seasoned Market Access professional with demonstrated leadership in Access strategy, Pricing and Patient Affordability Initiatives. Since joining in January 2024 as Market Access Lead, Venkat has been instrumental in building and strengthening the Market Access function.</p> <p>He has driven strategic access initiatives, expanded patient support programs, and advanced state-level access models and has also played a key role in pricing initiatives, PPILT, strengthening governance of patient services &amp; PAP, exploring private insurance partnerships, enabling alternative funding pathways, and securing product listings across multiple states and state insurance schemes.</p> <p>Prior to this, Mr. Natarajan held Market Access roles across organizations like Pfizer, Novartis, and MSD, contributing to building access models across segments of govt, insurance, and self-pay segments.</p> <p>In his earlier assignments, he has successfully led programs enabling affordability and access models for Asia and Eastern Europe markets for new launches, while leading the development of innovative affordability solutions including differential pricing and patient support</p>

		<p>establishing scientific leadership through industry-leading external partnerships. He also brings rich experience from participating in multiple studies as an investigator and uses that expertise to lead evidence generation across the continuum of the patient journey, addressing key unmet needs.</p> <p>Currently, he is serving as the Interim Medical Director for Oncology at AstraZeneca India, overseeing the end-to-end medical and diagnostics portfolio in oncology and defining strategy, guiding evidence generation, and strengthening partnerships to advance precision care and measurable patient outcomes.</p>	<p>programs to enhance patient access. He has also managed effective reimbursement strategy, stake-holder engagement and policy advocacy initiatives, including leading impactful National Programs improving affordability and access.</p> <p>With around two decades of experience in pharmaceutical industry, academically, Mr. Natarajan holds a Master's degree in Biochemistry along with advanced management qualifications including General Management Program from Indian School of Business &amp; PDGBA in Marketing from Symbiosis Institute of Management Studies.</p>
4	Disclosure of relationships between directors	Not Applicable	Not Applicable